A recent study (Clin Gastroenterol Hepatol 2014; 12: 1887-93) shows that patients with ulcerative colitis (UC) with subclinical activity, based on fecal calprotectin levels, improve with mesalamine escalation. DEAR, the acronym for this study, stands for Dose Escalation And Remission.
Methods: The researchers screened 119 patients with UC who were considered to be in remission based on the Simple Clinical Colitis Activity Index score. 52 patients who had calprotectin > 50 mcg/g and were receiving no more that 3 g/day of mesalamine were identified and switched to a mesalamine MMX 2.4 g/day dose for 6 weeks. Then the group was divided into an escalation group (4.8 g/day) or control group (continued with 2.4 g/day) for an additional 6 weeks.
- 26.9% of the escalation group and 3.8% of the control group achieved a calprotectin <50 mcg/g.
- 52.6% of the escalation group and 15.8% of the control group achieved a calprotectin <100 mcg/g.
- 76.9% of the escalation group and 16.7% of the control group achieved a calprotectin <200 mcg/g.
This study shows that higher doses of mesalamine were more effective in improving the calprotectin biomarker; however, the exact target value for calprotectin is not entirely clear. This study is in agreement with several others which have suggested a dose-response relationship with mesalamine therapy. This study suggests that a “quiescent” ulcerative colitis by scoring indices may overestimate the extent of colitis control. However, the associated editorial (pg 1894) cautions that “the current data are not sufficient to warrant the use of mesalamine dose escalation in patients with UC in clinical remission who have an increased FC (fecal calprotectin) concentration greater than 50 mcg/kg.”
Also noted: Clin Gastroenterol Hepatol 2014; 12: 1865-70. Prospective study of 59 patients with UC with clinical and endoscopic remission. 18 (30.5%) had histologic inflammation which correlated with elevated fecal calprotectin: median 278 mcg/g compared with 68 mcg/g for those without histologic inflammation.
Take-away message: If histologic inflammation is important, then fecal calprotectin can help identify this in patients otherwise considered to be in remission.
Related blog posts:
- CCFA Conference Notes 2014 (part 1) | gutsandgrowth
- CCFA Conference Notes 2014 (part 2) | gutsandgrowth
- Predicting long-term response with calprotectin levels …
- Calprotectin: Part of diagnostic algorithm for IBD …